Aurora Kinase A Inhibition Provides Clinical Benefit, Normalizes Megakaryocytes, and Reduces Bone Marrow Fibrosis in Patients with Myelofibrosis: A Phase I Trial

Overview of attention for article published in Clinical Cancer Research, August 2019

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (91st percentile)
Good Attention Score compared to outputs of the same age and source (79th percentile)

Mentioned by

news: 1 news outlet
twitter: 25 X users

facebook: 3 Facebook pages

Readers on

mendeley: 48 Mendeley

So far, Altmetric has seen 26 X posts from 25 X users, with an upper bound of 196,566 followers.

RT @DraettaG: At long last: Aurora Kinase A Inhibition Provides Clinical Benefit, Normalizes Megakaryocytes, and Reduces Bone Marrow Fibros…

At long last: Aurora Kinase A Inhibition Provides Clinical Benefit, Normalizes Megakaryocytes, and Reduces Bone Marrow Fibrosis in Patients with Myelofibrosis: A Phase I Trial https://t.co/ywhQ4hW9GR

RT @CCR_AACR: Phase I Study: Targeting megakaryocyte induced fibrosis in the myeloproliferative neoplasms. #myelofibrosis https://t.co/sc6m…

Phase I Study: Targeting megakaryocyte induced fibrosis in the myeloproliferative neoplasms. #myelofibrosis https://t.co/sc6m2m2UnU https://t.co/gUvIHHeJMq

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 22 additional X posts.